Prevagen: Seven Years of Litigation Over a Chart

what did the ftc and the ny ag actually allege in 2017?

The FTC and the New York attorney general filed a joint complaint against Quincy Bioscience on January 9, 2017, in the Southern District of New York (No. 1:17-cv-00124, FTC matter 152 3206), alleging the company deceptively marketed its Prevagen supplement as a memory and cognitive-function aid. Named defendants included Quincy Bioscience Holding Co., Quincy Bioscience LLC, Prevagen Inc. d/b/a Sugar River Supplements, Quincy Bioscience Manufacturing LLC, and co-founders Mark Underwood and Michael Beaman — the corporate form did not shield either of them from being named personally.

The alleged claims were specific, not vague.

The complaint says Quincy marketed Prevagen as a product that "improves memory, provides cognitive benefits, and is 'clinically shown' to work" — three separate representations, and under the FTC Act each one needed its own scientific backing rather than borrowing credibility from the others.

why was the substantiation, not the memory claim itself, the theory?

The theory was substantiation, not the subject of memory itself. FTC's press release announcing the case said the marketers "relied on a study that failed to show that Prevagen works better than a placebo on any measure of cognitive function" — a claim about missing evidence, not about whether memory claims are legal to make.

This is the detail most industry chatter gets backward: FDA's structure/function rule, the non-disease-claim lane for supplements, doesn't forbid memory claims at all. FDA's own 2000 rulemaking states plainly that "a claim to improve memory or strength would be a permitted structure/function claim, unless disease treatment were implied." The ceiling here sits with FTC's separate evidence bar, not FDA's disease-claim line.

We checked that evidence bar against the specific study Prevagen leaned on. The FTC Health Products Compliance Guidance sets substantiation at randomized, controlled human clinical testing for health-benefit claims, and FTC said the underlying study cleared that bar only for a narrow slice of one subgroup — not the general population the national ad campaign targeted.

what made the on-screen chart the exposure?

The chart was the exposure, not the underlying supplement claim.

FTC's complaint says television spots for Prevagen on CNN, Fox News and NBC showed charts depicting rapid, dramatic memory improvement — visuals implying a clean clinical result the underlying study didn't produce. A chart is easier for a viewer to remember than a footnote is, and FTC's theory leaned on exactly that asymmetry: a company can hedge its script while its imagery still overclaims.

Manufactured proof takes different shapes across FTC's supplement docket, a misleading chart in one case and a wave of fabricated ratings in another, as in Fake Amazon Reviews: FTC's First Supplement Case — but the complaint is usually the same one: the visual promises more than the study behind it can carry.

why were the two co-founders named individually?

FTC and the New York AG named Mark Underwood and Michael Beaman personally because they co-founded and ran Quincy Bioscience, not merely because they owned stock in it. FTC's Bureau of Consumer Protection, its consumer-facing enforcement arm, applies a control-or-participation standard broad enough to reach a founder who approved the ad copy without personally writing a line of it.

That exposure isn't unique to memory offers: The Neuropathy Case That Ended a Supplement Company shows the same personal-liability pattern closing a whole business, not just retiring one product line.

Naming both founders also meant the case couldn't be resolved by simply rebranding or dissolving the corporate shell.

how did a dismissal and a second circuit revival stretch it to seven years?

A district-court dismissal, followed by a revival from the Second Circuit, New York's federal appeals court, on February 21, 2019, is what turned Prevagen into a seven-year fight instead of a two-year settlement. Each stage added years of discovery, expert reports and motion practice before the case ever reached a jury.

what did the november and december 2024 orders require?

The court's late-2024 orders required Quincy Bioscience to stop making the specific memory and cognitive-benefit claims FTC challenged, not — on the public record available here — to fund a disclosed consumer-redress program. The court issued a Memorandum and Judgment on November 18, 2024 and an Order on December 6, 2024.

FTC's December 10, 2024 case-page statement said the court "ordered Quincy Bioscience to cease making claims about Prevagen that mislead Americans concerned about memory loss," following what FTC called seven years of hard-fought litigation, including a jury trial.

That is a narrower remedy than the refund checks some FTC supplement cases produce, the kind detailed in $3.5M in Refunds at $33 a Check: The Redress Math.

No settlement fund means no per-check number to report here.

what does 'preyed on the fears of older consumers' signal about creative?

It signals that FTC reads audience-targeting language as evidence, not just as marketing flavor. The Bureau of Consumer Protection director said "the marketers of Prevagen preyed on the fears of older consumers experiencing age-related memory loss," tying the enforcement theory directly to who the ads were built to reach.

The complaint's own numbers describe that buyer: $24 to $68 per 30-pill bottle, more than $165 million in total sales, distributed through Amazon, CVS, Vitamin Shoppe and Walgreens. That documents an older, retail-comfortable, high-average-order-value purchaser for one brand's enforcement record — it isn't a survey of who buys memory supplements today.

If your offer speaks to an adult child buying for a parent rather than to the parent directly, the fear-based framing risk still follows the money, not the age printed on the label.

what would a memory offer have to hold to survive the same complaint?

It would need a randomized, controlled human trial showing the claimed effect against a placebo on the exact measure advertised — the evidence Prevagen's marketers didn't have when the ad ran.

The available data suggests a workable ceiling, and it runs directly through FDA's own 2000 rulemaking: mild memory problems associated with aging are not treated as a disease, which is what makes an age-related memory claim legal to run at all, and FDA has separately said it would not read a claim to improve absentmindedness as an Alzheimer's treatment claim, because absentmindedness is a condition suffered predominantly by people who don't have Alzheimer's or any other disease. That leaves real room to say a product supports memory in ordinary aging. What it doesn't leave room for is Prevagen's actual failure mode: a chart built from a subgroup analysis, presented as though it represented the general population the ad targeted, in support of a claim strong enough that FTC could call it a promise rather than a description.

We could not verify how today's memory-supplement buyer differs from the one documented in 2017. AARP's Global Council on Brain Health publishes a supplement-and-brain-health report that likely carries current usage and spending figures, but we did not retrieve the underlying document, so we aren't quoting a number from it here. Pulling that report is what would settle the caregiver-versus-patient buyer question this page can't close.

Your ad doesn't need to avoid memory as a topic. It needs a study that would still hold up after someone turns it into a chart.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Best Nutra Affiliate Networks: Ranked by Offer Depth, Probiotic Weight Loss Offers: The Gut-Slim Ad Angle, Best GEOs for Nutra Offers in 2026: A Data Tier List, Supplement Ad Spy: How to Find Scaling Nutra Ads Fast, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.